ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
Globe Newswire•30/09/2026•06:55 ET
0
Key Highlights
- ➤SYNCHRONICITY Phase 4 data to be presented in a late-breaking oral session October 9, 2026
- ➤NEW DAY Phase 4 rescued-versus-non-rescued DME analyses to be presented as an on-demand ePoster
- ➤ILUVIEN (ANIP) indicated for chronic non-infectious posterior segment uveitis
- ➤Encore SYNCHRONICITY presentation planned for January 21, 2027
Expert Statements
David Almeida, MD, PhD, MBA, President and CEO of Erie Retina Research, and Principal Investigator in SYNCHRONICITY
“Presenter: David Almeida, MD, PhD, MBA, President and CEO of Erie Retina Research, and Principal Investigator in SYNCHRONICITY”
Christina Y Weng, MD, MBA, Professor and Alice R. McPherson Retina Research Foundation Chair in Ophthalmology, Baylor College of Medicine
“Presenter: Christina Y Weng, MD, MBA, Professor and Alice R. McPherson Retina Research Foundation Chair in Ophthalmology, Baylor College of Medicine”
Victor Gonzalez, MD
“The Company also plans to share an encore presentation of the Phase 4 SYNCHRONICITY results during a podium presentation by Victor Gonzalez, MD, on January 21, 2027, at the Hawaiian Eye & Retina 2027 Meeting.”
Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026
Post-hoc analyses of baseline characteristics and efficacy outcomes in rescued and non-rescued patients from the Phase 4 NEW DAY trial will be presented in an on-demand ePoster
Get started
Create a free account to read the full story.